Episode #138
John Bertrand on FDA Approval, CMS Reimbursement, and AI Healthcare Reality
Guest: John Bertrand, former Digital Diagnostics Episode Description Joe Grogan sits down with John Bertrand, a veteran healthcare technology executive who scaled Digital Diagnostics to 75 health systems and achieved the first FDA approval and CMS reimbursement for an autonomous AI diagnostic device without a physician in the diagnostic loop. Bertrand reveals the harsh realities of bringing AI innovation to market: FDA and CMS regulatory frameworks are built for traditional medical devices and physician-driven care, not autonomous AI diagnostics. The conversation covers the shocking CMS reimbursement draft that came in 40-60% below cost of goods sold, the massive first-mover disadvantage in regulated medical device AI, and why reimbursement is the true gating factor for adoption—not clinical superiority. Bertrand explains how workflow integration and financial incentives matter far more than being clinically better. The episode explores the massive gap between what entrepreneurs think should happen with new innovations and the regulatory reality. He concludes with a sobering assessment: if building diagnostic AI again, he would choose supply chain automation instead because the regulatory and reimbursement headwinds are so significant they punish innovators. Where AI is actually making an impact today is patient-facing triage agents, administrative automation, and revenue cycle management—areas with far less friction. KEY TIMESTAMPS 0:40 Joe introduces John Bertrand and his healthcare tech background 1:28 John clarifies he recently left Digital Diagnostics for supply chain work 2:40 John's career: 13 years at Epic Systems across multiple roles 6:10 What does Digital Diagnostics' AI device do? Automating retinal imaging 7:56 First FDA approval and first CMS reimbursement for autonomous AI diagnostic 9:02 Joe's threshold question: shouldn't better innovation be easily adopted? 9:50 Reality: workflow integration and reimbursement matter more than clinical quality 11:50 The adoption curve: all successful FDA-approved AI devices have CMS reimbursement 14:10 FDA experience: desire to help but frameworks built for old technology 15:40 FDA scrutiny on AI exceeds scrutiny on human clinicians 18:05 FDA guidance changes every 6-12 months, creating constant pivoting and delays 20:08 Shifting to CMS: the shocking draft reimbursement story 20:45 Draft came in at $10 per test, needed $30+ to be viable 22:42 Four months of negotiations with CMS to shift value argument 24:40 Process not codified: each company follows unique regulatory path 28:04 Six years at Digital Diagnostics: was it worth it? 28:44 John would not recommend diagnostic AI to new founders 33:02 Turning down multiple diagnostic AI opportunities post-Digital Diagnostics 34:19 AI hype vs reality: where are patients actually seeing life improvements? 34:19 Patient-facing triage agents are the second inning of real AI opportunity 36:25 Reimbursement for chat-based triage: who gets paid? 38:23 Autonomous vs assistive AI: the regulatory gap that exists 40:31 Could Digital Diagnostics have done physician-in-loop from the start? 41:33 Real opportunity: clinical practices deploying their own AI 42:20 State licensing nightmare: deploying AI across 50 states 44:55 The real concern: RCM automation becoming a zero-sum AI bot battle 45:20 Dead Internet Theory applied to healthcare revenue cycle 47:38 Closing: a tour de force on AI healthcare reality Key Topics AI in healthcare, FDA approval process, CMS reimbursement, autonomous AI diagnostics, Digital Diagnostics, diabetic retinopathy, regulatory frameworks, first-mover disadvantage, workflow integration, reimbursement strategy, patient-facing AI, healthcare innovation, regulatory friction, adoption barriers, state licensing, RCM automation, healthcare AI reality About the Guest John Bertrand is a veteran healthcare technology executive with over 20 years of experience. He spent 13 years at Epic Systems in analyst, product manage
